SELLAS Life Sciences Group, Inc. Convertible Preferred Stock Converted to Other Securities
SELLAS Life Sciences Group, Inc. (SLS) reported Convertible Preferred Stock Converted to Other Securities of $0 for the 3-month period ending 2019-09-30, per its 10-Q filed 2019-11-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ConvertiblePreferredStockConvertedToOtherSecurities · last filed 2020-03-13
- SELLAS Life Sciences Group, Inc. convertible preferred stock converted to other securities for the quarter ending 2019-09-30 was $0.00, a 100.00% decline year-over-year.
- SELLAS Life Sciences Group, Inc. convertible preferred stock converted to other securities for the quarter ending 2018-09-30 was $8.65M.
| Period end | Convertible Preferred Stock Converted to Other Securities | Convertible Preferred Stock Converted to Other Securities 3 month | Convertible Preferred Stock Converted to Other Securities 9 month |
|---|---|---|---|
| 2019-09-30 | $0.00 10-Q · filed 2019-11-14 | $0.00 10-Q · filed 2019-11-14 | |
| 2018-09-30 | $8.65M 10-Q · filed 2019-11-14 | $8.65M 10-Q · filed 2019-11-14 | |
| 2018-07-16 | $7.87M 10-K · filed 2020-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |